Lawsuit Overview - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is pending in the U S District Court for the Central District of California under the case Patel v Edwards Lifesciences Corporation et al No 24-cv-02221 [2] - Investors have until December 13 2024 to ask the Court to be appointed as lead plaintiff [2] Allegations Against Edwards Lifesciences - Edwards Lifesciences is accused of making materially false and misleading statements regarding its TAVR platform and its ability to capitalize on unmet demand [4] - The company allegedly overstated the demand and growth potential of TAVR while its patient activation activities failed to reach the low-treatment-rate population [4] - Healthcare organizations prioritized other treatments over TAVR leading to underutilization despite the company's claims of a significantly undertreated patient population [5] Financial Impact - On July 24 2024 Edwards Lifesciences slashed its guidance for TAVR for fiscal 2024 and announced disappointing financial results for TAVR in fiscal 2Q 24 [5] - The news caused a 31% decline in Edwards stock price from $86 95 per share on July 24 2024 to $59 70 per share on July 25 2024 [6] Company Background - Edwards Lifesciences is an international company that researches develops and provides products and technologies for heart valve repair and replacement therapies as well as critical care monitoring solutions [3] - The company categorizes its therapies and technologies into four segments: Transcatheter Aortic Valve Replacement (TAVR) Transcatheter Mitral and Tricuspid Therapies (TMTT) Surgical Structural Heart therapies and Critical Care therapies [3] Legal Representation - Bleichmar Fonti & Auld LLP is representing plaintiffs in this securities class action and shareholder litigation [8] - The firm has a track record of recovering significant amounts in similar cases including $900 million from Tesla Inc's Board of Directors and $420 million from Teva Pharmaceutical Ind Ltd [8]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/edwards-lifescie ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109666&from=3 CLASS PERIO ...

RADNOR, Pa., Oct. 29, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Edw ...

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims related to misleading statements about the company's TAVR platform and its market demand [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221 [2]. - Investors have until December 13, 2024, to request to lead the case [2]. Group 2: Company Overview - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, as well as critical care monitoring solutions, categorizing its offerings into four main areas: TAVR, TMTT, Surgical Structural Heart therapies, and Critical Care therapies [3]. Group 3: Allegations and Impact - The complaint alleges that Edwards misrepresented the demand for its TAVR platform, claiming significant unmet demand while the actual growth had stalled due to ineffective patient activation activities and prioritization of other treatments by healthcare organizations [4]. - On July 24, 2024, Edwards reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for the second quarter, leading to a 31% decline in stock price from $86.95 to $59.70 per share [5][6]. Group 4: Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs, with a contingency fee structure meaning no upfront costs for shareholders [7][8].

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/edwards-lifesciences-l ...

Core Viewpoint - Edwards Lifesciences Corporation is facing a class action lawsuit due to allegations of misleading investors regarding the growth prospects of its Transcatheter Aortic Valve Replacement (TAVR) platform [1][3]. Group 1: Company Disclosures and Performance - Throughout the class period, Edwards Lifesciences assured investors of "strong sustainable growth" for the TAVR platform, projecting healthy double-digit growth and the potential for acceleration in 2025 and beyond [2]. - The company later revealed that TAVR sales grew only 5% and reduced its growth guidance from 8-10% to 5-7% [4]. - The decline in TAVR growth was attributed to increased competition from structural heart therapies, which impacted hospital workflows [4]. Group 2: Investor Reactions and Market Impact - Following the disappointing Q2 2024 results, analysts downgraded Edwards Lifesciences shares and lowered their price targets, questioning the company's explanations regarding physician capacity versus demand [4]. - The share price dropped by $27.25, a decrease of 31%, resulting in a loss of over $16 billion in shareholder value in a single day [4]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating whether Edwards Lifesciences misled investors about the TAVR business and growth prospects amid increasing competition [5]. - The firm encourages investors who suffered losses to submit their claims and provides information for whistleblowers with non-public information [5].

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...